Suven Life Sciences announces first subjects dosed in phase-1 clinical trial of SUVN-I6107

The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs

President Murmu addresses Golden Jubilee Celebrations of NIMHANS

Inaugurates new facilities to further NIMHANS’ mission of delivering cutting-edge care in mental health and neurosciences

AbbVie completes acquisition of Aliada Therapeutics

Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease

Bristol Myers Squibb showcases cardiovascular portfolio at AHA Scientific Sessions 2024

Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS

Medanta to operate and manage 750 bed super speciality hospital in Pitampura, New Delhi

Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years

AbbVie to acquire Aliada Therapeutics

Strengthening focus in Alzheimer's disease and neuroscience pipeline

Lupin acquires nine brands of Medical Nutritional Institute in South Africa

MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome

Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant

The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025

Suven Life Sciences announces positive topline results from Phase-2 PoC signal detection open label study of Ropanicant

The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD

DKSH partners with Hasten Biopharmaceutical’s growth in Thailand